DOCSLIB.ORG

Citrine Medicine Advances Efforts to Create the Very First Rare Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Citrine Medicine Advances Efforts to Create the Very First Rare Disease Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant) Citrine was founded by Eight Roads, F-Prime Capital, and Vivo Capital; and closed an $80 Million Series A nancing earlier this year Company is focused on bringing important rare disease therapies to China while accelerating the rare disease drug development process worldwide Wakix® will address high unmet medical need for the treatment of people with narcolepsy in China NEWS PROVIDED BY Citrine Medicine Oct 28, 2020, 07:00 ET SHANGHAI and BOSTON, Oct. 28, 2020 /PRNewswire/ -- Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has entered into a development and licensing agreement with Bioprojet SCR (Bioprojet), a private French company focused on the design, synthesis and development of novel classes of drugs for unmet medical needs. The partnership provides Citrine with exclusive rights to develop, register, market, and manufacture Wakix® (pitolisant) in China for the treatment of narcolepsy and obstructive sleep apnea. / Citrine is a therapeutics platform company that is developing the rst rare disease ecosystem in China by creating a new paradigm for helping patients, families, and physicians through the introduction of much-needed drugs for orphan diseases. In addition to developing and marketing rare disease drugs, the company aims to establish a patient- centric platform which educates people on rare diseases, trains doctors on diagnosis and treatment, and helps doctors develop a full disease management protocol. Citrine, founded by Eight Roads, F-Prime Capital, and Vivo Capital, recently closed an $80 million Series A nancing led by Quan Capital, a China-based, healthcare-focused venture capital rm. The three founding investors, together with 3H Health Investment and WU Capital, also participated in the round. Rebecca Lin, Partner at Eight Roads Ventures and a member of Citrine's Board of Directors, stated: "At Eight Roads, our aspiration is to bring about positive change to society by backing innovative and meaningful businesses, and this mission underlies our founding investment in Citrine. We believe Citrine is well positioned to build an ecosystem in China to support patients suffering from rare diseases. The partnership with Bioprojet represents the company's rst effort to bring in validated medicines for patients in need. We look forward to supporting Citrine in its continued efforts to strengthen its capabilities and pipeline, while accelerating rare and orphan disease drug development both in China and globally." Dr. Dandan Dong, a Managing Director at Vivo Capital and a co-founder of Citrine Medicine, said: "Vivo has long been a believer in the global orphan drug development effort, and we are strong supporters of companies that seek to help rare disease patients. In co-founding Citrine, we extended this belief to the Greater China market. We are pleased to see that Citrine is bringing Wakix® to China for use in people with narcolepsy, a disease with signicant unmet medical need. We will continue to support Citrine in bringing more rare disease therapies to Chinese patients." "Great strides have been made in rare disease research and drug development in recent years; however, access to both knowledge and treatment options has been a barrier for rare disease patients in China," said Chong Xu, Ph.D., Principal at F-Prime Capital and a Citrine Medicine Board Director. "Recent regulatory reforms and policy changes in China are paving the way for an expedited drug approval pathway for rare disease drugs, and Citrine is poised to leverage this positive environment to deliver much-needed therapies to the people who need them. We believe the partnership with Bioprojet to bring pitolisant to patients in China is a great rst step towards that vision. F-Prime has long been committed to founding and / investing in companies that aim to transform healthcare, and we will continue to join forces with investors and founders to support Citrine in truly making a difference in the lives of individuals with rare diseases and their families in China." Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist that enhances the activity of histaminergic neurons and was developed after decades of research by Bioprojet co-founders Dr. Jeanne-Marie (J.M.) Lecomte and Prof. Jean-Charles Schwartz. Pitolisant increases the release of the brain chemical histamine to increase a patient's wakefulness and alertness. It is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to treat adults suffering from narcolepsy, a serious, chronic disorder characterized by excessive daytime sleepiness (EDS), with or without cataplexy. Currently no drugs have been ofcially approved by the National Medical Products Administration (NMPA) in China for the treatment of narcolepsy. There is a high unmet medical need for the treatment of narcolepsy patients with and without cataplexy in China. "We're excited that we are able to research, develop, and seek approval in China for Wakix®, a potential rst-in-class therapy to treat patients with narcolepsy," said Citrine CEO, Ben Wu. "In addition to working with the NMPA, Citrine will be working closely with healthcare providers, advocacy organizations, and other stakeholders to help address the unmet needs of the patient community." "Bioprojet is proud to partner with Citrine to help bring pitolisant to additional patients in need. With our collaborative best-in-class approach, we plan to help bring much needed relief to thousands of people suffering from debilitating sleep-related disorders," said Prof. Schwartz, discoverer of the histaminergic neurotransmission in brain and of the H3 receptor. Prof. Schwartz is the co-founder of Bioprojet with Dr. J.M. Lecomte. About Citrine Medicine Citrine (Shanghai) Co. Ltd. is a China-based biopharmaceutical therapeutics company dedicated to developing innovative therapies for patients with rare and intractable diseases by making diagnosis and essential treatments available and accessible for those who need them. Citrine is headquartered in Shanghai and has ofces in Beijing, China and Cambridge, Mass. / About Bioprojet SCR Bioprojet SCR is a research-based pharmaceutical company. Bioprojet is headquartered in Paris, France and its Research Center located in Rennes, France. Its activity is focused on the design, synthesis and development of novel classes of drugs for unmet medical needs. For more information visit http://www.bioprojet.com. About Pitolisant Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist which enhances the activity of histaminergic neurons. The drug was approved by the EMA in 2016 for the treatment of narcolepsy in adults with or without cataplexy and is marketed in major countries in Europe and was approved by the FDA in 2018. Cataplexy is characterized by sudden and uncontrolled muscle weakness or paralysis. Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy. The drug pitolisant is distributed under the tradename WAKIX® in the European Union and the United States for the treatment of narcolepsy in adult patients with and without cataplexy. About Narcolepsy Narcolepsy is a rare, chronic, debilitating neurological disorder characterized by excessive daytime sleepiness, cataplexy, a sudden loss of muscle control triggered by emotions, and hallucinations among other symptoms. Two types of narcolepsy are currently recognized according to the ICSD3 diagnostic criteria, Type 1 and 2. Type 1 is associated with cataplexy and a reduction in of hypocretin-1 levels, while Type 2 is not associated with cataplexy. Important Safety Information In clinical trials conducted in patients with narcolepsy, the most frequent adverse drug reactions (ADRs) reported with pitolisant were insomnia (8.4%), headache (7.7%), nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness (1.4%), depression (1.3%), tremor (1.2%), sleep disorders (1.1%), fatigue (1.1%), vomiting (1.0%), vertigo (1.0%), dyspepsia (1.0%), weight increase (0.9%), and upper abdominal pain (0.9%). Pitolisant is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in women breastfeeding their children. About Eight Roads Eight Roads is a global proprietary investment rm backed by Fidelity. The exible nature of its capital means Eight Roads can back and build innovative and ambitious businesses looking to disrupt or lead their chosen markets. Eight Roads has over 20 years of venture / capital experience in China and has supported over 100 companies in the country's healthcare and technology sectors. In the past 10 years, the Eight Roads ecosystem has invested almost $6 billion USD globally. About Vivo Capital Founded in 1996, Vivo Capital is a global investment rm focused on healthcare. Vivo has approximately $4.3 billion in assets under management, invested in over 250 public and private companies worldwide. Vivo provides a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. The rm is headquartered in Palo Alto, California, with additional ofces in Asia. About F-Prime Capital F-Prime Capital is a global venture capital rm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. With over two billion dollars under management and a global portfolio of more than 190 companies, we champion those dedicated to creating positive change in the world. F-Prime is headquartered in Cambridge, MA, with ofces in London, UK and San Francisco, CA. Citrine Medicine Media Contacts: Sarah Sutton Glover Park Group [email protected] 202-337-0808 Danielle Cantey Glover Park Group [email protected] 202-337-0808 SOURCE Citrine Medicine /.
Load more

Recommended publications
  • Entrepreneurship in Spain
    All you need to know about entrepreneurship in Spain June 2021 edition A way to make Europe EUROPEAN REGIONAL DEVELOPMENT1 FUND CONTENT Part I – STARTING POINT • Creating a startup Part II – RESOURCES FOR STARTUPS • Resources for startups • Incubators • Accelerators • Specific services suppliers Part III – FINANCING FOR STARTUPS • How to obtain financing • Private sector • Public sector • European calls • National calls Part IV – EVENTS FOR STARTUPS • Events Part V – AUTONOMOUS REGIONS • Programs and subsidies for startups This guide is intended as a collection of resources for startups in their different stages of seeking public and/or private funding 2 Part I Starting point CREATING A STARTUP IN SPAIN The steps to establish a startup are the same as for any other company. The very first one is to determine the most appropriate legal form, a decision that will be influenced by the startup´s later needs regarding participation deals and receipt of third-party investment. The most used legal forms are: Spain • Limited Liability Company (Sociedad Limitada, S.L.) in • Corporation (Sociedad Anónima, S.A.). startup Both forms can also be set up as a sole-shareholder entity (Sociedad Anónima Unipersonal, S.A.U. and Sociedad Limitada Unipersonal, S.L.U. respectively) a at the time of incorporation or be converted into a sole-shareholder entity afterwards. While there are alternatives to these legal forms, they aren´t advisable for startups that will be seeking to add partners to the project and/or third-party investors. For information purposes, these include: Freelancer (Autónomo), Private partnership (Sociedad Civil) or Jointly-Owned Entity (Comunidad de creating Bienes), or a Cooperative (Cooperativa).
    [Show full text]
  • Venture Capital Focus
    Private Investing in India – Venture Capital Focus State of Sector Report November 2019 Contents Foreword .................................................................................................................................... 4 Executive Summary .................................................................................................................. 6 Indian Macroeconomic Environment .................................................................................... 10 Indian Macroeconomic Environment ................................................................................... 11 Indian Economy’s March towards USD 5 Trillion GDP ................................................ 11 Private Investing in India ........................................................................................................ 14 Private Investments in India ................................................................................................ 15 India’s share of global private investing is ~3% and Asian private investing is ~15%. 15 India’s affair with the private capital transalting into a solid commitment ..................... 19 Private Equity in India ............................................................................................................. 21 Private Equity in India ................................................................................................... 22 Total PE Investment in India......................................................................................... 22 Average
    [Show full text]
  • The 58 Most Active Venture Capital Firms for Startups in India
    The 58 Most Active Venture Capital Firms For Startups In India (and their investing patterns) ©2018 Inc42 All Rights Reserved Feel free to share this ebook without modification. 1 Introduction Once a startup has reached the growth stage, its most important requirement is undoubtedly the backing by reliable investors and an ample amount of funding to scale up. Though the concept of starting up has gained momentum recently, the small number of investors willing to show their trust and invest in new ventures has been a problem for startups. Many startups find it difficult to approach venture capitalists and quite a few times the investment structure of the investor is inadequate for the startup. So in this document, we bring to you the much needed list of the most active institutional investors and capital funds in India along with their investment capacity, investment structure, investment industries and some of their most notable portfolio startups. 2 Helion Venture Partners Investing in technology-powered and consumer service businesses, Helion Ventures Partners is a $605 Mn Indian- focused, an early to mid-stage venture fund participating in future rounds of financing in syndication with other venture partners. People You Should Know: Sandeep Fakun, Kanwaljit Singh. Investment Structure: Invests between $2 Mn to $10 Mn in each company with less than $10 Mn in revenues. Industries: Outsourcing, Mobile, Internet, Retail Services, Healthcare, Education and Financial Services. Startups Funded: Yepme, MakemyTrip, NetAmbit, Komli, TAXI For Sure, PubMatic. Contact Details: 8040183333, 01244615333, 3 Accel Partners Accel Partners founded in 1983 has global presence in Palo Alto, London , New York, China and India.
    [Show full text]
  • Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 3/19/2018 – 3/23/2018 (Transactions in Excess of $20 Million)
    Private Capital Group Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 3/19/2018 – 3/23/2018 (Transactions in excess of $20 million) Trends & Commentary ▪ This week, 15 U.S. private placement deals between $20 million and $50 million closed, accounting for $452 million in total proceeds, compared to last week’s 13 U.S. deals leading to $421 million in total U.S. Corporate VC Activity $ in Billions proceeds. This week also had 6 U.S. deals between $50 million and $100 million yielding $365 million, $50 compared to last week’s 5 deals resulting in $341 million in total proceeds. 1,379 ▪ U.S. corporate venture capital deal volume has grown over the past decade from $10.0 billion in 2008 to $45 1,283 1,268 $37.4 billion in 2017. The number of deals has increased as well, from 674 in 2008 to 1,268 in 2017. (see 1,231 $40 figure) ▪ Dropbox priced its IPO at $21 per share and traded up 40% on its opening to close at $28.48 a share. The $35 1,045 Company raised $756 million and had an initial market cap of more than $8.0 billion. Dropbox previously raised $350 million in Series C funding at a $9.7 billion pre-money valuation from BlackRock in 2014. $30 829 713 ▪ Zscaler, a provider of a global cloud security platform, priced its IPO last week at $27.50 per share, raising $25 674 $192 million. The Company had originally planned to sell 10 million shares between $10 and $12 a share.
    [Show full text]
  • Investor Allstars Brochure 2015.Pdf
    1 OCTOBER 2015 – THE LANCASTER, LONDON www.investorallstars.com #investorallstars 1 Welcome 2015 – The Year ofthe Unicorn! If last year was defined by a series of high-profile exits, 2015 has seen a shift towards entrepreneurs raising vast rounds of capital for long-term growth. No longer are our talented entrepreneurs satisfied with $100 million trade sales. Many are choosing to stay independent for longer and create global leaders of unprecedented scale. The European digital ecosystem will look back on this as ‘The Year of the Unicorn’ – the moment when European unicorns started reaching globally competitive valuations. Our audience tonight has played a major role in nurturing the $40 billion+ companies charging across Europe, and it is fantastic to see mega-funds such as KKR, General Atlantic, TCV and BlackRock now entrenched as a core part of the funding chain for fast-growth companies. Our standout companies are reaching scale faster than at any point in history – with the often-cited five years for Uber to create $10 billion of value vs 15 years for Microsoft to create $1 billion being replicated by our audience tonight – HelloFresh, BlaBlaCar, Spotify, Klarna, Avito, Funding Circle, JUST EAT… To support these disruptors, the funding ecosystem needs to evolve, and while we have many parts working efficiently, we still witness a strong dependence on the US for $50 million+ expansion rounds. Within five years I would love to see us pulling together to allow our star entrepreneurs the choice of raising locally or overseas. It is vital that we become better at raising awareness for some truly great achievements.
    [Show full text]
  • R N Marwah & Co
    The Velocity of Risk In a time of instant crises, internal auditors and their stakeholders need a sense of urgency to identify and manage risk. RNM ALERT A MONTHLY R N MARWAH & NEWSLETTER CO. LLP www.rnm.in PUBLICATION VOL NO 123 RNM MONTHLY, APRIL 2019 EDITORIAL TEAM R N MARWAH & CO. LLP RNM ALERT R N MARWAH & CO LLP W: www.rnm.in E: [email protected] T: 011 - 43192000 AUDIT & ASSURANCE TAX & REGULATORYNkdckjksj k j vcjjvjasvjjjjavjvn Welcome Readers, CORPORATE & LEGAL Dear Readers, CORPORATE The month of April 2019 saw voting in India in large parts with widespread voter participation in a FINANCE true strength of India‘s democratic fabric. Team RNM urges all of you to exercise your franchise by voting. On a separate note, Team RNM offers its condolences to the victims of Cyclone storm ‗Fani‘ which has hit the eastern coast of India and left large devastation in its wake. The new GST changes in Real Estate sector which have kicked in from April 1, 2019 have far reaching Content: impact in trying to incentivize the flagging fortunes of this important sector of the economy. 1.5% rate is now applicable on Affordable Residential Apartments and 7.5% rate is applicable to Other than WELCOME Affordable Residential Apartments and Commercial Apartment. The said rates come with certain Message by our safeguards and existing projects as on 31.3.2019 have the option of going with old rates of 8% or 12% Managing partner with input tax credits or new rates without input tax credit. 03 DIRECT TAX Corporate Legal Department has been busy this past month with the new changes introduced.
    [Show full text]
  • Global Fintech Weekly August 8, 2019
    Thursday Global FinTech Weekly August 8, 2019 Highlight of the week –Time to modernize China Rmb 40trn personal wealth management market? Figure 1: New product launch by banks WM subsidiaries Source: Bank website China’s Rmb 40-50trn personal wealth management market is lagging behind in technology adoption According to CBRC, the outstanding wealth management products (WMPs) reached RMB32trn at YE18. We estimate the personal wealth management market size to be at about RMB40-50trn, which is currently scattered in bank WMPs, mutual funds, insurance, trusts, P2P, etc. The new asset management rules require the banks to separate their wealth management units from parent banks and launch independent WM subsidiaries by the end of 2020. Among the “Big 6”, CCB, ICBC, BOCOM and BOC have already launched their WM subsidiaries; ABC has been approved to open and PSBS has been approved to establish its WM sub. Spin out banks’ wealth management business is the first step to break the guaranteed return in WM markets and establish the firewall between the banks’ balance sheet and WMPs. By now, there is still a long way to go for WMP product innovation and technology adoption. AMTD Research Michelle Li +852 3163-3383 [email protected] Robo-advisors may empower China’s personal wealth management market Technology adoption is more common in payment and online consumer lending, etc., but there is limited application in China’s wealth management, except for micro-investment market dominated by Alibaba’s Yu’ebao. After a few years of market hype, robo-advisory has not yet achieved high market recognition.
    [Show full text]
  • NOAH Berlin 2018
    Table of Contents Program 7 Venture Capital 10 Growth 126 Buyout 150 Debt 165 2 Table of Contents Venture Capital Growth 3TS Capital Partners 11 ECONA 50 Project A 92 Accel Partners 128 83North 12 Eight Roads 51 PropTech1 Ventures 93 Activant Capital 129 ACT Ventures 13 Endeit Capital 52 ProSiebenSat.1 Accelerator 94 BlackFin Capital Partners 130 Acton Capital Partners 14 FJ Labs 53 QD Ventures 95 Burda Principal Astutia Ventures 15 Fluxunit - OSRAM Ventures 54 Redalpine 96 Investments 131 Atlantic Labs 16 Frog Capital 55 Redline Capital 97 CapitalD 132 Aventures 17 General Catalyst 56 Red-stars.com data AG 98 Egmont 133 Axa Venture Partners 18 German Media Pool 57 Redstone 99 EMK Capital 134 b10 19 German Startups Group 58 RTA Ventures 100 General Atlantic 135 BackBone Ventures 20 Global Founders Capital 59 RTP Global 101 GPI Capital 136 Balderton Capital 21 Global Ventures 60 Samos Investments 102 Great Hill Partners 137 BCG Digital Ventures 22 GPS Ventures 61 Schibsted Growth 103 Horizon Capital 138 Beringea 23 GR Capital 62 Seventure Partners 104 HPE Growth Capital 139 Berlin Technologie Holding 24 Griffon Capital 63 SevenVentures 105 Insight Venture Partners 140 Bessemer Venture Partners 25 Hammer Team 64 SmartFin 106 LetterOne 141 BFB Brandenburg Kapital 26 Hearst Ventures 65 SpeedInvest 107 NGP Capital 142 BMW iVentures 27 High-Tech Gruenderfonds 66 SpeedUp Venture Capital NuCom Group 143 Boerse Stuttgart Digital Holtzbrinck Ventures 67 Group 108 Scottish Equity Partners 144 Ventures 28 i5invest 68 STIHL Digital 109 Stripes Group
    [Show full text]
  • Annual Deal Tracker
    Annual Deal List February 2020 Contents Section Page M&A 04 Domestic 05 Mergers and internal restructuring 16 M&A: Inbound 17 M&A: Outbound 21 Private equity 25 IPO 62 QIP 64 Disclaimer This document captures the list of deals announced based on information available in the public domain and based on public announcements. Grant Thornton India LLP does not take any responsibility for the information, any errors or any decision by the reader based on this information. This document should not be relied upon as a substitute for detailed advice and hence, we do not accept responsibility for any loss as a result of relying on the material contained herein. Further, our analysis of the deal values is based on publicly available information and based on appropriate assumptions (wherever necessary). Hence, if different assumptions were to be applied, the outcomes and results would be different. This document contains the deals announced and closed as of 20 December 2019. 02 Industry 4.0: Transforming the manufacturing landscape Annual Deal List 2019 0 3 M&A 04 Annual Deal List 2019 I. Domestic Acquirer Target Sector USDm % Stake Reliance Strategic Business Asteria Aerospace Pvt. Ltd. Aerospace and defence 3.30 52% Ventures Limited Ashok Leyland Ltd. Ashley Aviation Ltd. Aerospace and defence 0.08 27% PI Industries Ltd. Isagro (Asia) Agrochemicals Private Limited Agriculture and forestry 49.00 100% Luxmi Tea Co. Pvt. Ltd. Mcleod Russel India Ltd. - Specified assets of Agriculture and forestry 21.43 100% Addabarie Tea Estate, Mahakali Tea Estate and Dirai Tea Estate Mahindra CIE Automotive Ltd.
    [Show full text]
  • Main Conference Agenda
    Last update on 2 November 2020 MAIN CONFERENCE AGENDA The timing is set according to HKT (UTC+8). The agenda is subject to further changes. Last update on 2 November 2020 Monday, Nov 2 Hong Kong Channel Future Channel Growth Channel FinTech Studio OfficiaL Opening Programme Starts at 11:00 Programme Starts at 11:00 Programme Starts at 11:00 10:00 - 10:10 • Paul Chan Mo-po, GBM, GBS, MH, jP, Financial Secretary, Hong Kong Special Administrative Region Government Hong Kong Regulators Atom Bank, 86400 Founder Startups Funding StruggLe & From Consumer to InstitutionaL on Making Neobanks Is the Party Over for cLients - Citi’s Take on CLient Opening Keynote Centricity Through FinTech ProfitabLe Neobanks? 10:10 - 10:25 11:00 - 11:20 11:00 - 11:15 11:00 - 11:15 • Eddie Yue, jP, Chief Executive, Hong Kong • Morgan McKenney, Chief Operating Officer of Monetary Authority • Anthony Thomson, Chairman & • jonathan Larsen, Chief Innovation Officer/ Global Consumer Banking, Citi Co-Founder, 86 400 Chairman & CEO, Ping An Group/ Ping An Global Voyager Fund • Moderator: Charlotte Crosswell, CEO, Innovate Finance • Moderator: Melissa Guzy, Co-Founder & Managing Partner, Arbor Ventures Hong Kong Regulators Virtual Banks SMEs VC & Investing Virtual Banks Regulations & RegTech Capital Markets Hong Kong VC & Investing How WeBank Became Big By CVCs vs VCs: What Do CentraL Banks in the DigitaL Focusing On The SmaLL Company Investment Arms Economy 11:15 - 11:35 Bring To The TabLe For On Mapping Out The WhoLe 10:25 - 11:10 Startups China Market Into One Giant •
    [Show full text]
  • The Rise of Wealthtech
    WWW.DRAKESTAR.COM JULY 2020 Sector Report THE RISE OF WEALTHTECH Julian Ostertag, Managing Partner and Christophe Morvan, Managing Partner Member of the Executive Committee [email protected] [email protected] +33 1700 876 10 +49 89 1490 265 20 Michael Metzger, Partner Antonia Georgieva, Partner [email protected] [email protected] +1 310 696 4011 +1 917 755 5518 Kasper Kruse Petersen, Partner [email protected] +44 203 2057 360 In the USA, all securities transacted through Drake Star Securities LLC. In the USA, Drake Star Securities LLC. Is regulated by FINRA and is a member of SIPC Drake Star Partners is the marketing name for the global investment bank Drake Star Partners Limited and its subsidiaries and affiliates. In the USA, all securities are transacted through Drake Star Securities LLC. In the USA, Drake Star Securities LLC is regulated by FINRA and is a member of SIPC. © 2020 Drake Star Partners. This report is published solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security. The information herein is based on sources we believe to be reliable but is not guaranteed by us and we assume no liability for its use. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. Citations and sources are available upon request through https://www.drakestar.com/contact. Interviews were conducted by Drake Star Partners via email correspondence between March and May 2020.
    [Show full text]
  • Stashaway Insights 2020
    StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 StashAway Insights 2020 For press inquiries contact Amanda Ong Head of Client Engagement and PR [email protected] +65 91507507 or visit stashaway.com/press Follow us linkedin.com/company/stashaway facebook.com/StashAwayAPAC instagram.com/stashaway_com Produced by StashAway Asia Wealth Platform Pte Ltd in 2020 Contents 01 Introduction 1 02 A look into investor behaviour in a market correction 7 03 Debunking myths about digital wealth managers 21 04 How StashAway is bridging the financial literacy gap 27 1 Introduction 2 Introduction Foreword by Michele Ferrario It has been quite a ride since we launched StashAway in Singapore in July 2017.
    [Show full text]